Patient preferences for advanced hepatocellular carcinoma treatment: a multicountry stated preference study

This study was sponsored by Sirtex Medical United Kingdom Ltd. Suki Shergill, Fabien Colaone, Victoria K Brennan, Vincenzo A Straccia and Ion Agirrezabal are employees of Sirtex Medical, a manufacturer of yttrium-90 microspheres used for the treatment of hepatocellular carcinoma. Siu Hing Lo, Daniel Aggio and Andrew J Lloyd are employees of Acaster Lloyd Consulting and received funding from Sirtex Medical in support of this study. Rohini Sharma reports advisory roles for Advanced Accelerator Applications (AAA), Eisai, Roche and Sirtex Medical, and research grants from, AAA, Astex Pharmaceuticals and Boston Scientific. Charlotte E Costentin reports advisory roles for Intercept, Ipsen and Sirtex Medical, speaker bureau roles for AbbVie, Intercept and Ipsen, research grants from Gilead, and travel and accommodation expenses from AbbVie, Biotest, Gilead, Intercept and Ipsen. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

留言 (0)

沒有登入
gif